Home|||||||Technical Support|

GABA transporter 1 antibody - 274 102

GATs are neurotransmitter transporters involved in the termination of GABA transmission
Polyclonal rabbit antiserum
Cat. No.: 274 102
Amount: 200 µl
Price: $350.00
Cat. No. 274 102 200 µl antiserum, lyophilized. For reconstitution add 200 µl H2O, then aliquot and store at -20°C until use.
Applications WB: 1 : 1000 (AP staining) (see remarks) gallery  
IP: yes
ICC: 1 : 500 up to 1 : 1000 gallery  
IHC: 1 : 500 up to 1 : 1000 gallery  
IHC-P/FFPE: 1 : 500 gallery  
Immunogen Synthetic peptide corresponding to AA 585 to 599 from mouse GABA transporter1 (UniProt Id: P31648)
Reactivity Reacts with: rat (P23978), mouse (P31648).
Other species not tested yet.
Specificity Specific for GAT 1. K.O. PubMed: 33664860
Matching control protein/peptide 274-1P
Remarks

WB:  GABA transporter 1 aggregates after boiling, making it necessary to run SDS-PAGE with non-boiled samples.

Data sheet 274_102.pdf

References for GABA transporter 1 - 274 102

GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model.
Roberts BM, Doig NM, Brimblecombe KR, Lopes EF, Siddorn RE, Threlfell S, Connor-Robson N, Bengoa-Vergniory N, Pasternack N, Wade-Martins R, Magill PJ, et al.
Nature communications (2020) 111: 4958. 274 102 WB, IHC; tested species: mouse
Environmental enrichment implies GAT-1 as a potential therapeutic target for stroke recovery.
Lin Y, Yao M, Wu H, Wu F, Cao S, Ni H, Dong J, Yang D, Sun Y, Kou X, Li J, et al.
Theranostics (2021) 118: 3760-3780. 274 102 IHC; KO verified; tested species: mouse
GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model.
Roberts BM, Doig NM, Brimblecombe KR, Lopes EF, Siddorn RE, Threlfell S, Connor-Robson N, Bengoa-Vergniory N, Pasternack N, Wade-Martins R, Magill PJ, et al.
Nature communications (2020) 111: 4958. 274 102 WB, IHC; tested species: mouse
Cat. No.: 274 102
Quantity: 200 µl
Price: $350.00
GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model.
Roberts BM, Doig NM, Brimblecombe KR, Lopes EF, Siddorn RE, Threlfell S, Connor-Robson N, Bengoa-Vergniory N, Pasternack N, Wade-Martins R, Magill PJ, et al.
Nature communications (2020) 111: 4958. 274 102 WB, IHC; tested species: mouse
Environmental enrichment implies GAT-1 as a potential therapeutic target for stroke recovery.
Lin Y, Yao M, Wu H, Wu F, Cao S, Ni H, Dong J, Yang D, Sun Y, Kou X, Li J, et al.
Theranostics (2021) 118: 3760-3780. 274 102 IHC; KO verified; tested species: mouse
GABA uptake transporters support dopamine release in dorsal striatum with maladaptive downregulation in a parkinsonism model.
Roberts BM, Doig NM, Brimblecombe KR, Lopes EF, Siddorn RE, Threlfell S, Connor-Robson N, Bengoa-Vergniory N, Pasternack N, Wade-Martins R, Magill PJ, et al.
Nature communications (2020) 111: 4958. 274 102 WB, IHC; tested species: mouse
Background
γ-aminobutyric acid (GABA) is a major inhibitory neurotransmitter. After the release of GABA from synaptic vesicles into the synaptic cleft during neurotransmission, GABA transporters (GATs) remove extracellular GABA by reuptake into the presynaptic terminal.
Three GABA transporters are described so far of which only GAT 1 and GAT 3 are expressed in the brain.